Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!

EPZM Insider Trading (Epizyme)

Insider Ownership Percentage: 16.30%
Insider Buying (Last 12 Months): $1,054,514.57
Insider Selling (Last 12 Months): $3,239,295.61

Epizyme Insider Trading History Chart

Epizyme Share Price & Price History

$10.19
▼ -0.22 (-2.11%)
As of 02/24/2021 01:00 AM ET
Days: 30 | 90 | 365
This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

Epizyme Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/4/2021Paolo TombesiCFOSell1,021$11.21$11,445.4153,465  
2/4/2021Robert B BazemoreCEOSell3,890$11.21$43,606.90331,977  
2/4/2021Shefali AgarwalInsiderSell969$11.21$10,862.49104,341  
1/25/2021Matthew RosInsiderSell2,872$11.41$32,769.52  
1/25/2021Robert B. BazemoreCEOSell6,069$11.41$69,247.29  
12/3/2020Shefali AgarwalInsiderSell2,522$13.54$34,147.8876,089  
11/11/2020Carl GoldfischerDirectorBuy5,000$12.07$60,350.005,000  
9/3/2020Joseph BeaulieuInsiderSell971$12.77$12,399.67  
6/26/2020David M MottDirectorBuy62,019$16.03$994,164.5782,601  
6/26/2020Joseph BeaulieuInsiderSell317$16.15$5,119.555,155  
6/26/2020Paolo TombesiCFOSell1,805$16.15$29,150.7523,747  
6/26/2020Robert B BazemoreCEOSell4,773$16.15$77,083.95254,871  
6/18/2020Matthew RosInsiderSell112,003$21.24$2,378,943.7292,861  
6/18/2020Robert B BazemoreCEOSell20,000$22.00$440,000.00264,371  
3/25/2020Joseph BeaulieuInsiderSell212$15.28$3,239.365,173  
3/25/2020Paolo TombesiCFOSell1,243$15.28$18,993.0416,680  
3/25/2020Robert B BazemoreCEOSell3,285$15.28$50,194.8080,726  
3/3/2020Joseph BeaulieuInsiderSell996$22.18$22,091.28  
1/27/2020Robert B BazemoreCEOSell6,074$20.44$124,152.5693,744  
1/27/2020Shefali AgarwalInsiderSell2,630$20.44$53,757.2063,276  
1/24/2020Robert B BazemoreCEOSell3,002$24.62$73,909.2493,744  
1/24/2020Shefali AgarwalInsiderSell1,843$24.64$45,411.5263,276  
6/26/2019David M MottDirectorSell104,944$13.08$1,372,667.5213,979  
6/13/2019Matthew RosInsiderSell1,185$12.10$14,338.5040,217  
6/13/2019Robert B BazemoreCEOSell2,074$12.10$25,095.4087,068  
10/5/2018David M MottDirectorBuy416,667$9.00$3,750,003.0012,088  
See Full Table

SEC Filings (Institutional Ownership Changes) for Epizyme (NASDAQ:EPZM)

89.82% of Epizyme stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Epizyme Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021MPM Oncology Impact Management LP2,331,534$25.32M4.3%-18.3%2.295%
2/23/2021Principal Financial Group Inc.37,572$0.41M0.0%+17.6%0.037%
2/17/2021Voloridge Investment Management LLC183,932$2M0.0%N/A0.181%
2/17/2021Jane Street Group LLC59,975$0.65M0.0%+55.3%0.059%
2/16/2021Squarepoint Ops LLC36,159$0.39M0.0%-55.0%0.036%
2/16/2021Morgan Stanley1,869,246$20.30M0.0%+29.0%1.840%
2/16/2021Tudor Investment Corp Et Al112,644$1.22M0.0%+81.7%0.111%
2/16/2021Nuveen Asset Management LLC365,556$3.97M0.0%-9.8%0.360%
2/16/2021Price T Rowe Associates Inc. MD1,542,587$16.75M0.0%-2.7%1.519%
2/16/2021ExodusPoint Capital Management LP36,402$0.40M0.0%+154.2%0.036%
2/16/2021Charles Schwab Investment Management Inc.607,660$6.60M0.0%+0.6%0.598%
2/13/2021American International Group Inc.51,850$0.56M0.0%-2.8%0.051%
2/12/2021Penserra Capital Management LLC2,330$25K0.0%+169.1%0.002%
2/12/2021LPL Financial LLC22,496$0.24M0.0%+14.8%0.022%
2/12/2021The Manufacturers Life Insurance Company 53,808$0.58M0.0%+2.9%0.053%
2/12/2021Credit Suisse AG200,712$2.18M0.0%+16.3%0.198%
2/12/2021Virtus ETF Advisers LLC46,638$0.51M0.2%+38.4%0.046%
2/11/2021Northern Trust Corp1,003,372$10.90M0.0%-5.6%0.988%
2/11/2021Barclays PLC135,710$1.47M0.0%-7.3%0.134%
2/11/2021Citigroup Inc.50,179$0.55M0.0%+73.0%0.049%
2/11/2021Slow Capital Inc.44,879$0.49M0.1%+13.3%0.044%
2/11/2021Frazier Management LLC731,436$7.94M0.6%N/A0.720%
2/10/2021Rhumbline Advisers152,481$1.66M0.0%+0.9%0.150%
2/9/2021Wells Fargo & Company MN69,780$0.76M0.0%+56.2%0.069%
2/9/2021ProShare Advisors LLC35,437$0.39M0.0%+29.8%0.035%
2/8/2021Primecap Management Co. CA15,208,527$165.17M0.1%+0.9%14.972%
2/8/2021Russell Investments Group Ltd.74,720$0.81M0.0%-6.7%0.074%
2/5/2021BlackRock Inc.7,911,028$85.91M0.0%+3.1%7.788%
2/5/2021Aperio Group LLC15,083$0.16M0.0%N/A0.015%
2/5/2021SG Americas Securities LLC15,892$0.17M0.0%-71.1%0.016%
2/4/2021State of Wisconsin Investment Board126,800$1.38M0.0%-11.1%0.125%
2/1/2021Victory Capital Management Inc.2,667,977$28.97M0.0%-3.5%2.626%
1/28/2021Perigon Wealth Management LLC18,237$0.20M0.0%+34.6%0.018%
1/25/2021XTX Markets LLC11,434$0.12M0.3%N/A0.011%
1/22/2021Candriam Luxembourg S.C.A.105,890$1.15M0.0%-70.7%0.104%
1/20/2021Pacer Advisors Inc.5,508$60K0.0%+34.4%0.005%
1/19/2021DNB Asset Management AS20,744$0.23M0.0%N/A0.020%
1/12/2021North Star Investment Management Corp.139,800$1.52M0.2%+18.1%0.138%
12/14/2020Strs Ohio30,859$0.37M0.0%-6.4%0.030%
12/11/2020Virtu Financial LLC19,347$0.23M0.0%N/A0.019%
11/19/2020MPM Oncology Impact Management LP2,854,737$34.06M8.2%+22.4%2.810%
11/17/2020Paloma Partners Management Co22,183$0.27M0.0%N/A0.022%
11/17/2020Twinbeech Capital LP14,972$0.18M0.0%N/A0.015%
11/17/2020Jane Street Group LLC38,618$0.46M0.0%+7.1%0.038%
11/16/2020Cubist Systematic Strategies LLC8,206$98K0.0%-34.6%0.008%
11/16/2020Point72 Asset Management L.P.332,673$3.97M0.0%+198.0%0.327%
11/16/2020AQR Capital Management LLC61,825$0.74M0.0%-45.9%0.061%
11/16/2020Squarepoint Ops LLC80,371$0.96M0.0%+11.5%0.079%
11/16/2020ExodusPoint Capital Management LP14,318$0.17M0.0%-48.2%0.014%
11/16/2020Boothbay Fund Management LLC10,934$0.13M0.0%N/A0.011%
11/13/2020Morgan Stanley1,449,327$17.29M0.0%+111.1%1.427%
11/13/2020Allianz Asset Management GmbH294,956$3.52M0.0%+3.4%0.290%
11/13/2020ProShare Advisors LLC27,291$0.33M0.0%-3.5%0.027%
11/13/2020Charles Schwab Investment Management Inc.604,142$7.21M0.0%+11.6%0.595%
11/13/2020UBS Asset Management Americas Inc.63,103$0.75M0.0%-8.5%0.062%
11/13/2020Virtus ETF Advisers LLC33,686$0.40M0.2%+9.2%0.033%
11/13/2020Williams Jones Wealth Management LLC.127,155$1.52M0.0%N/A0.125%
11/12/2020JPMorgan Chase & Co.280,576$3.38M0.0%-32.0%0.276%
11/12/2020AlphaCrest Capital Management LLC31,500$0.38M0.0%+140.5%0.031%
11/10/2020State Street Corp4,442,413$53M0.0%+16.2%4.378%
11/9/2020SG Americas Securities LLC54,895$0.66M0.0%+387.7%0.054%
11/9/2020The Manufacturers Life Insurance Company52,280$0.62M0.0%-1.7%0.052%
11/9/2020Victory Capital Management Inc.2,765,292$32.99M0.0%+20.4%2.725%
11/9/2020LPL Financial LLC19,596$0.23M0.0%+11.5%0.019%
11/9/2020Swiss National Bank160,300$1.91M0.0%+1.8%0.158%
11/6/2020BlackRock Inc.7,672,267$91.53M0.0%+1.0%7.561%
11/6/2020Trexquant Investment LP48,260$0.58M0.0%N/A0.048%
11/6/2020GSA Capital Partners LLP79,582$0.95M0.2%N/A0.078%
11/6/2020Aigen Investment Management LP117,430$1.40M0.2%N/A0.116%
11/5/2020California Public Employees Retirement System202,239$2.41M0.0%+2.5%0.199%
11/5/2020Alps Advisors Inc.129,409$1.54M0.0%-6.1%0.128%
11/5/2020Wells Fargo & Company MN44,661$0.53M0.0%-28.0%0.044%
11/4/2020American International Group Inc.53,338$0.64M0.0%-2.2%0.053%
11/4/2020Slow Capital Inc.39,605$0.47M0.1%+74.1%0.039%
11/4/2020Alps Advisors Inc.129,409$1.54M0.0%-6.1%0.128%
11/4/2020Mackay Shields LLC107,200$1.28M0.0%+27.8%0.106%
11/3/2020CIBC Private Wealth Group LLC456,904$5.45M0.0%N/A0.450%
11/3/2020Perigon Wealth Management LLC13,553$0.16M0.0%N/A0.013%
11/2/2020Teacher Retirement System of Texas189,218$2.26M0.0%+0.9%0.186%
10/30/2020BNP Paribas Arbitrage SA20,851$0.25M0.0%+104.0%0.021%
10/29/2020Dupont Capital Management Corp29,472$0.35M0.0%-17.4%0.029%
10/29/2020DekaBank Deutsche Girozentrale20,900$0.25M0.0%N/A0.021%
10/29/2020Altfest L J & Co. Inc.17,079$0.20M0.1%+18.9%0.017%
10/20/2020Wedbush Securities Inc.26,450$0.32M0.0%+3.1%0.026%
10/20/2020Nisa Investment Advisors LLC4,500$54K0.0%+542.9%0.004%
10/19/2020Candriam Luxembourg S.C.A.361,152$4.31M0.0%+36.3%0.356%
10/19/2020Pacer Advisors Inc.4,099$49K0.0%N/A0.004%
10/13/2020North Star Investment Management Corp.118,400$1.41M0.2%+20.1%0.117%
9/25/2020Birchview Capital LP70,000$1.12M0.7%+16.7%0.069%
9/15/2020Two Sigma Advisers LP73,100$1.17M0.0%N/A0.072%
9/4/2020Principal Financial Group Inc.33,917$0.54M0.0%-31.2%0.033%
8/26/2020Handelsbanken Fonder AB18,200$0.29M0.0%N/A0.018%
8/25/2020Nuveen Asset Management LLC452,989$7.28M0.0%+19.9%0.446%
8/20/2020Charles Schwab Investment Management Inc.541,416$8.70M0.0%+12.7%0.534%
8/17/2020AQR Capital Management LLC114,206$1.83M0.0%-6.8%0.113%
8/17/2020California State Teachers Retirement System214,719$3.45M0.0%+81.9%0.212%
8/14/2020Caption Management LLC160,010$2.57M0.1%+137.1%0.158%
8/14/2020Man Group plc348,514$5.60M0.0%+1,314.3%0.343%
8/14/2020Point72 Hong Kong Ltd10,179$0.16M0.0%+1,838.9%0.010%
8/14/2020Point72 Asset Management L.P.111,620$1.79M0.0%N/A0.110%
Data available starting January 2016

See Full Table
Epizyme logo
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.19
$10.01
$10.62

50 Day Range

MA: $11.37
$10.41
$12.32

52 Week Range

Now: $10.19
$9.90
$23.61

Volume

967,840 shs

Average Volume

824,770 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Who are the company insiders with the largest holdings of Epizyme?

Epizyme's top insider investors include:
  1. Robert B Bazemore (CEO)
  2. Shefali Agarwal (Insider)
  3. Matthew Ros (Insider)
  4. David M Mott (Director)
  5. Paolo Tombesi (CFO)
  6. Joseph Beaulieu (Insider)
  7. Carl Goldfischer (Director)
  8. Robert B Bazemore (CEO)

Who are the major institutional investors of Epizyme?

Epizyme's top institutional shareholders include:
  1. Primecap Management Co. CA — 14.97%
  2. BlackRock Inc. — 7.79%
  3. Victory Capital Management Inc. — 2.63%
  4. MPM Oncology Impact Management LP — 2.30%
  5. Morgan Stanley — 1.84%
  6. Price T Rowe Associates Inc. MD — 1.52%

Which institutional investors are selling Epizyme stock?

Within the previous quarter, EPZM stock was sold by these institutional investors:
  1. MPM Oncology Impact Management LP
  2. Candriam Luxembourg S.C.A.
  3. Victory Capital Management Inc.
  4. Northern Trust Corp
  5. Squarepoint Ops LLC
  6. Price T Rowe Associates Inc. MD
  7. Nuveen Asset Management LLC
  8. SG Americas Securities LLC
During the previous year, company insiders that have sold Epizyme company stock include:
  1. Robert B Bazemore (CEO)
  2. Shefali Agarwal (Insider)
  3. Matthew Ros (Insider)
  4. David M Mott (Director)
  5. Paolo Tombesi (CFO)
  6. Joseph Beaulieu (Insider)

Which institutional investors are buying Epizyme stock?

Within the last quarter, EPZM stock was purchased by institutional investors including:
  1. Frazier Management LLC
  2. Morgan Stanley
  3. BlackRock Inc.
  4. Voloridge Investment Management LLC
  5. Primecap Management Co. CA
  6. Tudor Investment Corp Et Al
  7. Credit Suisse AG
  8. Wells Fargo & Company MN
Within the last year, these company insiders have bought Epizyme stock:
  1. Robert B Bazemore (CEO)
  2. Shefali Agarwal (Insider)
This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here